Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
11 lessons
9mResearchAdvanced
Tesamorelin and Liver Fat: Why the TESA-LIVER Trial Matters
Tesamorelin has one of the cleanest human-data stories in the peptide space. The new liver fat trial matters because it asks whether that signal extends into fatty liver disease.
8mResearchAdvanced
GLP-1s and Macular Degeneration: What the Eye Studies Say
GLP-1 research is moving beyond weight loss. Recent ophthalmology studies suggest possible links with age-related macular degeneration, but the signals are mixed and need careful interpretation.
7mResearchAdvanced
BPC-157 Hits a Milestone: The First Controlled Human Trial Is Now Recruiting
After 30+ years of animal research and 212 preclinical studies, BPC-157 has entered its first Phase 2 human trial. Here's what it will test, what it won't prove, and what to track.
8mResearchAdvanced
Tesamorelin and Visceral Fat: What the 2026 Meta-Analysis Shows
Tesamorelin has one of the stronger human-data profiles in the peptide space. A 2026 meta-analysis helps clarify what it improves, what it does not, and how to track the signal honestly.
9mResearchAdvanced
Retatrutide TRIUMPH-4: 28.7% Weight Loss and Osteoarthritis Relief in One Peptide
The TRIUMPH-4 trial delivers groundbreaking dual benefits: 28.7% body weight reduction plus significant osteoarthritis pain relief. Retatrutide's triple mechanism may solve two problems simultaneously.
9mResearchAdvanced
BPC-157 Human Trial: 87.5% of Knee Pain Patients Report Significant Relief at 6–12 Months
87.5% of patients with chronic knee pain reported significant relief after BPC-157 treatment at the 6–12 month follow-up. Here's a breakdown of the human trial data, the dosing protocol used, and why this peptide is getting serious clinical attention.
9mPeptidesIntermediate
BPC-157 and Wound Healing: The Science Behind the 'Body Protection Compound'
BPC-157 accelerates tissue repair by stimulating angiogenesis and collagen synthesis. Here's what the research shows and what users need to know.
10mPeptidesIntermediate
Why Retatrutide Preserves Muscle Better Than Tirzepatide
Rapid fat loss typically means muscle loss. But retatrutide's triple action—including glucagon receptor activation—preserves more lean mass than tirzepatide or GLP-1-only compounds. Here's the science.
12mPeptidesIntermediate
Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows
Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
10mPeptidesIntermediate
BPC-157: The Peptide That Heals Joints, Ligaments, and Muscle Faster
BPC-157 is showing remarkable promise in clinical research for rapid tissue regeneration. Learn how this pentapeptide works, what the data shows, and whether it's right for your recovery protocol.
12mPeptidesIntermediate
BPC-157: The Tendon Recovery Peptide Backed by Clinical Research
BPC-157 shows promise in clinical research for accelerating tendon repair and recovery. Learn how this peptide works and what the science says about its efficacy.
Also available at /blog for legacy links.